Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
Status:
Recruiting
Trial end date:
2022-07-22
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus
(CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a
virus that may be carried for life and does not cause illness in most healthy individuals.
However, in people whose immune systems are lowered (such as those undergoing stem cell
transplantation), CMV can reproduce and cause disease and even death. The Triplex vaccine is
made up of 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes)
placed into a weakened virus called modified vaccinia Ankara (MVA) that may help produce
immunity (the ability to recognize and respond to an infection) and reduce the risk of
developing complications related to CMV infection.